GLP-1 receptor agonists × adverse events & safety

TrialDiabetes care2022

Once-Weekly Exenatide in Youth With Type 2 Diabetes.

William V Tamborlane et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 83 people · 2022

Randomised comparison

Probably lowered adverse events & safety

−0.85percentage points−1.51 to −0.19

As reported

difference −0.85 %, 95% CI −1.51 to −0.19

One number in the abstract

the abstract, start to end

groups (between-group difference, -0.85%; 95% CI -1.51, -0.19; P =

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
−0.85−1.51 to −0.19
GLP-1 receptor agonistsAdverse events & safety

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely
0.020.02 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

52 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35679098